INNATE PHARMA SP.ADR/1 (IDDA) - Total Assets
Based on the latest financial reports, INNATE PHARMA SP.ADR/1 (IDDA) holds total assets worth €62.72 Million EUR (≈ $73.33 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
INNATE PHARMA SP.ADR/1 - Total Assets Trend (2021–2025)
This chart illustrates how INNATE PHARMA SP.ADR/1's total assets have evolved over time, based on quarterly financial data. Also see INNATE PHARMA SP.ADR/1 (IDDA) total market value for the company's overall valuation and market capitalisation.
INNATE PHARMA SP.ADR/1 - Asset Composition Analysis
Current Asset Composition (December 2025)
INNATE PHARMA SP.ADR/1's total assets of €62.72 Million consist of 74.5% current assets and 25.5% non-current assets. Review INNATE PHARMA SP.ADR/1 (IDDA) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 44.8% |
| Accounts Receivable | €391.00K | 0.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how INNATE PHARMA SP.ADR/1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See INNATE PHARMA SP.ADR/1 share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INNATE PHARMA SP.ADR/1's current assets represent 74.5% of total assets in 2025, an increase from 51.7% in 2021.
- Cash Position: Cash and equivalents constituted 44.8% of total assets in 2025, up from 38.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 16.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
INNATE PHARMA SP.ADR/1 Competitors by Total Assets
Key competitors of INNATE PHARMA SP.ADR/1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
INNATE PHARMA SP.ADR/1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 2.60 | 2.92 |
| Quick Ratio | 1.27 | 2.60 | 2.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €10.06 Million | €52.76 Million | €73.37 Million |
INNATE PHARMA SP.ADR/1 - Advanced Valuation Insights
This section examines the relationship between INNATE PHARMA SP.ADR/1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.05 |
| Latest Market Cap to Assets Ratio | 1.85 |
| Asset Growth Rate (YoY) | -43.5% |
| Total Assets | €62.72 Million |
| Market Capitalization | $116.15 Million USD |
Valuation Analysis
Above Book Valuation: The market values INNATE PHARMA SP.ADR/1's assets above their book value (1.85x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: INNATE PHARMA SP.ADR/1's assets decreased by 43.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below shows the annual total assets of INNATE PHARMA SP.ADR/1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €62.72 Million ≈ $73.33 Million |
-43.53% |
| 2024-12-31 | €111.06 Million ≈ $129.84 Million |
-36.61% |
| 2023-12-31 | €175.19 Million ≈ $204.81 Million |
-12.10% |
| 2022-12-31 | €199.29 Million ≈ $233.00 Million |
-25.50% |
| 2021-12-31 | €267.50 Million ≈ $312.73 Million |
-- |
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more